Citations - Mirza Mansoor Raza

CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Mirza Mansoor Raza
By: Bradley J Monk
CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Mirza Mansoor Raza
By: Bradley J Monk
CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Mirza Mansoor Raza
By: Bradley J Monk
CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Mirza Mansoor Raza
By: Bradley J Monk
CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Mirza Mansoor Raza
By: Bradley J Monk
CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.... Read more
Published on: 2020-08-22
Source: Mirza Mansoor Raza
By: Bradley J Monk
CONCLUSION: The results of this round table meeting could help redefine perspectives on the discussed topics and the importance for therapeutic management as well as for trial designs.... Read more
Published on: 2020-08-21
Source: Mirza Mansoor Raza
By: Robert Armbrust

Other Resources

Other Citations

Other Citations

News by Specialization

News by Specialization

Videos

Selection of Videos by Specialization

Latest News

Latest News

Translate »